Pygeum
A bark extract from the African cherry tree (Prunus africana) used mainly for benign prostatic hyperplasia (BPH) symptoms. Older RCTs show modest improvement in nocturia, urine flow, and overall symptoms; modern head-to-head trials vs alpha-blockers or 5-ARIs are sparse. Reasonable second-tier option for mild–moderate LUTS, not a substitute for proven medications when BPH is significant.
Quick decision guide
May help most
Men with mild-to-moderate lower urinary tract symptoms (LUTS) of BPH — nocturia, weak stream, hesitancy — who want a botanical option, or as an adjunct to medication.
Common dosing range
100–200 mg/day of a standardised lipidosterolic extract (often 50 mg twice daily), with food.
When to expect effects
4–8 weeks to assess symptom change.
Watch out for
BPH symptoms can mask prostate cancer; don't start any botanical without a baseline urology workup (PSA, DRE, symptom score).
Evidence snapshot
What is it
Pygeum is the common name for the bark extract of Prunus africana (formerly Pygeum africanum ), an evergreen tree native to the montane forests of sub-Saharan Africa. The bark contains a characteristic mixture of phytosterols (chiefly beta-sitosterol and its glycosides), pentacyclic triterpenes (ursolic and oleanolic acids), ferulic acid esters of long-chain fatty alcohols (n-docosanol, n-tetracosanol), and other lipophilic constituents. Standardised lipidosterolic extracts are most commonly used in supplements for benign prostatic hyperplasia and lower urinary tract symptoms. The species is CITES-listed owing to overharvesting; sustainably sourced cultivated material is increasingly preferred.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
Benign prostatic hyperplasia (BPH) — overall symptom improvement Good Evidence | Roughly 2x more likely to report symptom improvement vs placebo; ~20% improvement in nocturia, residual volume, peak flow | Men with mild-to-moderate BPH symptoms (IPSS 8–19), particularly nocturia-dominant | 4–8 weeks |
Nocturia (night-time urination) Good Evidence | ~19% reduction in night-time voids vs placebo over 4–8 weeks | Men with BPH whose dominant complaint is nocturia disrupting sleep | 4–8 weeks |
Chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS) Limited Evidence | Not reliably quantified | Men with CP/CPPS phenotype already managed by urology, as an adjunct trial | Weeks to months in case series |
Male sexual function or fertility Mixed Evidence | No reliable clinical-endpoint benefit demonstrated | None established for this indication | Not established |
Benign prostatic hyperplasia (BPH) — overall symptom improvement
- Effect
- Roughly 2x more likely to report symptom improvement vs placebo; ~20% improvement in nocturia, residual volume, peak flow
- Best fit
- Men with mild-to-moderate BPH symptoms (IPSS 8–19), particularly nocturia-dominant
- Time
- 4–8 weeks
Nocturia (night-time urination)
- Effect
- ~19% reduction in night-time voids vs placebo over 4–8 weeks
- Best fit
- Men with BPH whose dominant complaint is nocturia disrupting sleep
- Time
- 4–8 weeks
Chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS)
- Effect
- Not reliably quantified
- Best fit
- Men with CP/CPPS phenotype already managed by urology, as an adjunct trial
- Time
- Weeks to months in case series
Male sexual function or fertility
- Effect
- No reliable clinical-endpoint benefit demonstrated
- Best fit
- None established for this indication
- Time
- Not established
Evidence for 4 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
Benign prostatic hyperplasia (BPH) — overall symptom improvement
Supplement benefitA 2002 Cochrane review of 18 RCTs in 1,562 men found that pygeum extract more than doubled the likelihood of overall symptom improvement vs placebo (RR 2.1, 95% CI 1.4–3.1). Nocturia decreased ~19%, residual urine volume ~24%, and peak urine flow increased ~23%. The reviewers cautioned that trials were small, short-term, and used varied doses — and called for larger comparative trials, which have not since materialised at scale.
Bottom line: Real but modest benefit on symptom scores in old RCTs. Reasonable for mild BPH after a urologist has ruled out red flags. Don't expect tamsulosin-level effects.
Evidence is mixed
Most trials predate 2000 and used outcome measures that have since been standardised. No large modern RCTs vs alpha-blockers or 5-ARIs. NCCIH's 2024 review notes recent trials of botanicals for BPH have been less consistently positive than the early data.
Nocturia (night-time urination)
Supplement benefitNocturia is the most consistently reported pygeum endpoint. Across the Cochrane-pooled trials, nocturia frequency dropped ~19% vs placebo — clinically meaningful for sleep quality if you're up 2–3 times a night. Mechanism likely combines anti-inflammatory action (5-lipoxygenase inhibition) and weak androgen-receptor effects from atraric acid.
Bottom line: If your main BPH bother is getting up at night, this is the endpoint pygeum is most likely to move.
Chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS)
Supplement benefitA few small studies and uncontrolled case series suggest pygeum may reduce pelvic pain and inflammatory markers in CP/CPPS, but quality RCTs are lacking. The mechanism (5-LOX inhibition) is plausible. NCCIH and AUA guidelines do not endorse it as an established treatment.
Bottom line: Plausible but not proven for CP/CPPS. Not a first-line move; talk to your urologist.
Male sexual function or fertility
Mechanism onlySome marketing positions pygeum for libido, erectile function, or sperm health based on its prostate effects. Direct clinical evidence is minimal — small uncontrolled studies in idiopathic infertility report modest changes in semen parameters but lack control arms and modern methodology.
Bottom line: Marketing far outpaces evidence. Don't use pygeum specifically for sexual function or fertility.
How to take it
What to track
Bottom line: 100–200 mg/day standardised extract, with food, for 8–12 weeks. Always pair with a baseline urology evaluation — botanicals don't replace screening.
3 commercial forms
Compare the main delivery options and what they’re best suited for.
Standardised lipidosterolic extract
The studied formThe form used in essentially all Cochrane-pooled RCTs (often standardised to ~14% phytosterols). Capsules typically 50 or 100 mg; daily dose 100–200 mg.
The format with actual clinical data behind it.
Whole-bark powder
Less reliableCheaper but variable in active content. Phytosterol and atraric acid concentrations differ widely between batches. Not the form used in trials.
Inconsistent active content batch to batch.
Pygeum + saw palmetto + nettle combo
Popular but messyCommercial blends pair pygeum with saw palmetto and/or stinging nettle root. Convenient but makes it impossible to know which ingredient (if any) is doing the work. Trial evidence for combinations is mixed.
Hard to attribute any effect to pygeum specifically.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Symptom improvement from pygeum could mask progression of BPH or an undiagnosed prostate cancer. Always have a urology workup (PSA, DRE, symptom score) before starting and at usual intervals.
Long-term safety beyond 12 months is not well characterised — most RCTs ran 4–12 weeks.
Who should avoid it
- Men with untreated, unevaluated lower urinary tract symptoms — get a urology workup first.
- Pregnant or breastfeeding people (pygeum is not appropriate for non-male indications and safety data are absent).
- Anyone scheduled for prostate surgery within 2 weeks — discontinue and tell the surgical team.
Pregnancy & breastfeeding
Pygeum is used exclusively for male prostate indications; not indicated for women, and pregnancy/lactation safety data are absent.
Bottom line: Generally well tolerated. The biggest risk is using it instead of proper BPH evaluation. Always partner with a urologist.
Interactions
No reported pharmacokinetic interaction. Pygeum is often added on top of an alpha-blocker for additional symptom relief; monitor for any change in orthostatic blood pressure.
No documented interaction. Unlike finasteride, pygeum does NOT lower PSA, so PSA-based screening remains interpretable.
Theoretical only — phytosterols may have mild effects on platelet function. Notify your surgical team if you take pygeum and discontinue 1–2 weeks before surgery.
Often combined commercially. No evidence of harm or synergy. Use one or the other to assess effect cleanly.
Choosing a product
What to look for on the label — and what to be skeptical of.
Look for…
Be skeptical of…
References by claim
Benign prostatic hyperplasia (BPH) — overall symptom improvement
Track Pygeum with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.